According to Market Scope, Ethyreal Bio operates in the ophthalmic biotech space. The published item focuses on the company's recent $101 million Series A raise rather than on product specifics. The article does not detail Ethyreal Bio's lead programs, pipeline assets, or clinical-stage status. No company founding year, location, revenue, or user metrics were provided in the coverage. The report likewise does not specify planned uses of the Series A proceeds.

Total raised

$101M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2026